Today, (25th March 2010), Cyprotex announces that it has extended its Cloe® Screen Cytochrome P450 Inhibition service to include an additional cytochrome P450 isoform, CYP2B6. Our assay uses human liver microsomes and bupropion as the probe substrate – a protocol which is recommended by the draft FDA guidelines on drug interactions.
The inhibition of human cytochrome P450 enzymes is one of the most common mechanisms that can lead to drug-drug interactions. Metabolic drug-drug interactions, following the co-administration of drugs, can result in either reduced efficacy or increased toxicity. In early drug discovery it is critical to select candidates with a minimum potential of cytochrome P450 inhibition in order to avoid late stage issues or failures.
The importance of CYP2B6 in clinical interactions has been highlighted in a US FDA update paper by Huang et al., 2008 (J Clin Pharmacol 48; 662-670). This update advises that CYP2B6 should be included when assessing whether enzyme inhibition or induction has the potential to produce a drug interaction.
Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the launch of the extended service. ‘Identifying cytochrome P450 inhibition liability early in the drug discovery process is now commonplace within the Pharmaceutical Industry due to the prevalence and potential clinical implications of cytochrome P450 inhibition. Our unique Cloe® Screen technology couples robust protocols with state-of-the-art automation enabling Cyprotex to offer an unrivalled combination of high quality, cost effective data with rapid turnaround.’
For further information:
Swadipa Das, Marketing Manager
Tel: +44 1625 505 100